Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome
暂无分享,去创建一个
R. Mayeux | N. Schupf | P. Mehta | W. Silverman | M. Tang | D. Pang | W. Zigman | R. Mayeux | Wayne P Silverman | Wayne Silverman | W. Silverman
[1] F. Grodstein,et al. Ten-year change in plasma amyloid beta levels and late-life cognitive decline. , 2009, Archives of neurology.
[2] S. Hirai,et al. α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia , 1990 .
[3] P. Mehta,et al. Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.
[4] S. Younkin,et al. Plasma amyloid β protein is elevated in late-onset Alzheimer disease families , 2008, Neurology.
[5] C. Jack,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.
[6] K. Blennow,et al. CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry , 2003, Brain Research Bulletin.
[7] L. Buée,et al. Association of plasma amyloid β with risk of dementia , 2009, Neurology.
[8] D. Geschwind,et al. Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.
[9] N. Inestrosa,et al. Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood , 1995 .
[10] D. Selkoe,et al. Normal and abnormal biology of the beta-amyloid precursor protein. , 1994, Annual review of neuroscience.
[11] B. Tycko,et al. Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome , 2001, Neuroscience Letters.
[12] J. Sidtis,et al. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[13] M. Inglese,et al. Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment , 2004, Neurology.
[14] E. Matsubara,et al. Lipoprotein‐free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome , 1999, Annals of neurology.
[15] R. Petersen,et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.
[16] T. Tokuda,et al. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. , 1997, Annals of neurology.
[17] S A Small,et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. , 1999, Annals of neurology.
[18] A. Hofman,et al. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.
[19] B. Hyman,et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. , 2008, Archives of neurology.
[20] Anders Wallin,et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.
[21] H. Fukuyama,et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.
[22] I. Kloszewska,et al. Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. , 2005, Acta neurobiologiae experimentalis.
[23] A. Hofman,et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.
[24] E. Aylward,et al. Diagnosis of dementia in individuals with intellectual disability. , 1997, Journal of intellectual disability research : JIDR.
[25] P. Deyn,et al. No correlation between time-linked plasma and CSF Aβ levels , 2009, Neurochemistry International.
[26] T. Tokuda,et al. Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome , 1997 .
[27] P. Mehta,et al. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. , 2001, Neuroscience letters.
[28] G. Heinrich. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. , 1989, The New England journal of medicine.
[29] L S Honig,et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.
[30] H. Wiśniewski,et al. Increased plasma amyloid β protein 1–42 levels in Down syndrome , 1998, Neuroscience Letters.
[31] J. Hardy,et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.
[32] J. Growdon,et al. Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .
[33] J. Growdon,et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. , 2003, Archives of neurology.
[34] S. Hirai,et al. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. , 1990, Annals of neurology.
[35] K. Blennow,et al. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.
[36] S. Younkin,et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. , 2008, Neurology.
[37] N. Schupf,et al. Prevalence of dementia in adults with and without Down syndrome. , 1996, American journal of mental retardation : AJMR.
[38] B. Hyman,et al. Plasma Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men , 2008 .
[39] D. T. Vernier,et al. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.
[40] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[41] R. Petersen,et al. Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .
[42] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[43] R. Mayeux,et al. Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. , 2007, Archives of neurology.
[44] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[45] N. Schupf,et al. Dementia in adults with mental retardation: assessment at a single point in time. , 2004, American journal of mental retardation : AJMR.
[46] J. Growdon,et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. , 2008, Archives of neurology.
[47] N. Inestrosa,et al. Platelets are the primary source of amyloid beta-peptide in human blood. , 1995, Biochemical and biophysical research communications.
[48] H. Wiśniewski,et al. Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .
[49] R. Mayeux,et al. Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .
[50] H. Wiśniewski,et al. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. , 1998, Neuroscience letters.
[51] Henrik Zetterberg,et al. Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.